Based on the recent identification of TNFα as a potentially very important molecular target for RNAi therapy in leukemia (Kagoya et al., 2014), further development of the TNFα-siRNA harboring nanoparticles holds significant translational promise because of their anti-inflammatory, anti-angiogenic, and anti-leukemic potential. This evidence concerns the gene TNF and leukemia.